|Bid||66.10 x 900|
|Ask||66.15 x 1000|
|Day's range||65.98 - 66.83|
|52-week range||42.48 - 68.34|
|Beta (5Y monthly)||0.76|
|PE ratio (TTM)||33.02|
|Earnings date||22 Apr 2020 - 26 Apr 2020|
|Forward dividend & yield||1.80 (2.72%)|
|Ex-dividend date||01 Jan 2020|
|1y target est||73.40|
Updated CheckMate -025 Results Show 26% of Patients Treated with Opdivo are Alive at Five Years in Patients with Previously Treated Advanced...
Opdivo Plus Yervoy Demonstrates Continued Survival Benefit at 42-Month Follow-up in Patients with Previously Untreated Advanced or Metastatic RCC
Multinational IBDe Survey Uncovers Striking Differences in Patients’ and Physicians’ Treatment Goals and Disease Management Expectations
Bristol-Myers Squibb Company (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review its Biologics License Application (BLA) for lisocabtagene maraleucel (liso-cel), the company’s autologous anti-CD19 chimeric antigen receptor (CAR) T-cell immunotherapy with a defined composition of purified CD8+ and CD4+ CAR T cells for the treatment of adult patients with relapsed or refractory (R/R) large B-cell lymphoma after at least two prior therapies. The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date of August 17, 2020.
The Zacks Analyst Blog Highlights: Alibaba, Toyota Motor, Bristol-Myers Squibb, S&P Global and Uber Technologies
AC Immune (ACIU) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
DHT Holdings (DHT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 1 (Strong Buy).
Radian (RDN) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Fiat Chrysler (FCAU) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
It's been a good week for Bristol-Myers Squibb Company (NYSE:BMY) shareholders, because the company has just released...
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Bristol-Myers Squibb (BMY) have what it takes? Let's find out.
From understanding your risk tolerance to maintaining emotional control, achieving your retirement goals takes a much different investing approach than regular stock trading.
Bristol-Myers (BMY) beats both earnings and sales estimates in the fourth quarter, primarily on robust sales of Eliquis and acquisition of Celgene.
Bristol-Myers (BMY) delivered earnings and revenue surprises of 38.64% and 29.45%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Investing.com - Bristol-Myers Squibb (NYSE:BMY) reported on Thursday fourth quarter earnings that beat analysts' forecasts and revenue that topped expectations.